NASDAQ:APRE Aprea Therapeutics (APRE) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free APRE Stock Alerts $5.89 +0.30 (+5.37%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$5.54▼$5.9050-Day Range$5.07▼$8.2952-Week Range$2.78▼$8.85Volume8,820 shsAverage Volume26,372 shsMarket Capitalization$31.98 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aprea Therapeutics alerts: Email Address Aprea Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside163.2% Upside$15.50 Price TargetShort InterestHealthy1.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 9 Articles This WeekInsider TradingAcquiring Shares$71,952 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.38) to ($0.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.54 out of 5 starsMedical Sector801st out of 2,771 stocksPharmaceutical Preparations Industry341st out of 1,288 stocks 3.5 Analyst's Opinion Consensus RatingAprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aprea Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.90% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently decreased by 5.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APRE. Previous Next 2.7 News and Social Media Coverage News SentimentAprea Therapeutics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Aprea Therapeutics this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $71,952.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.90% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.19% of the stock of Aprea Therapeutics is held by institutions.Read more about Aprea Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.38) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aprea Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTruth about Trump you’ve never heardEverything about Donald Trump is public. Every part of his life has been dragged out in the media. But there’s one story I bet you’ve never heard about Trump. For the full story, click here. About Aprea Therapeutics Stock (NASDAQ:APRE)Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Read More APRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APRE Stock News HeadlinesMay 14 at 6:23 PM | markets.businessinsider.comBuy Rating Affirmed: Aprea Therapeutics’ Financial and Clinical ProgressMay 14 at 3:13 PM | investorplace.comAPRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024May 14 at 8:30 AM | globenewswire.comAprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business UpdateMay 13 at 4:01 PM | globenewswire.comAprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare ConferenceMay 7, 2024 | americanbankingnews.comAprea Therapeutics (NASDAQ:APRE) Trading Down 1.7%May 2, 2024 | markets.businessinsider.comAprea Therapeutics Appoints Mirza As CMOMay 2, 2024 | finance.yahoo.comAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.April 26, 2024 | finance.yahoo.comInterim Report - January-March 2024April 12, 2024 | markets.businessinsider.comAprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy RatingApril 10, 2024 | globenewswire.comAprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024April 3, 2024 | msn.comAprea Therapeutics files to sell 4.39M shares of common stock for holdersMarch 28, 2024 | markets.businessinsider.comAprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy RatingMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024March 26, 2024 | investorplace.comAPRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023March 26, 2024 | globenewswire.comAprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateMarch 20, 2024 | markets.businessinsider.comAprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug PipelineMarch 18, 2024 | msn.comAprea Therapeutics Secures Up to $34 Million in Groundbreaking Financing DealMarch 16, 2024 | uk.investing.comAprea Therapeutics CFO buys $7,362 in company stockMarch 16, 2024 | uk.investing.comAprea Therapeutics director buys $50k of company stockMarch 14, 2024 | finance.yahoo.comKarolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionMarch 14, 2024 | globenewswire.comKarolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionMarch 12, 2024 | markets.businessinsider.comAprea Therapeutics Secures Private Placement Financing Of Upto $34 MlnMarch 11, 2024 | msn.comWhy Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?March 11, 2024 | msn.comAprea Therapeutics announces private placement financing of up to $34MSee More Headlines Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/14/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APRE CUSIPN/A CIK1781983 Webwww.aprea.com Phone617-463-9385FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+163.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,290,000.00 Net MarginsN/A Pretax Margin-2,450.60% Return on Equity-65.58% Return on Assets-52.37% Debt Debt-to-Equity RatioN/A Current Ratio5.13 Quick Ratio5.13 Sales & Book Value Annual Sales$580,000.00 Price / Sales55.14 Cash FlowN/A Price / Cash FlowN/A Book Value$4.54 per share Price / Book1.30Miscellaneous Outstanding Shares5,430,000Free Float4,295,000Market Cap$31.98 million OptionableNo Data Beta1.08 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Oren Gilad Ph.D. (Age 56)Co-Founder, CEO, President & Director Comp: $520.84kMr. John P. Hamill CPA (Age 60)Senior VP, CFO, Principal Accounting Officer & Secretary Dr. Dansu Li Ph.D.Head of TechnologyDr. Lars B. Abrahmsen Ph.D. (Age 67)Senior VP & Chief Scientific Officer Dr. Michel Afargan Ph.D.Head of Pharmacology DevelopmentMr. Ze'ev Weiss B.Sc. (Age 62)C.P.A., Chief Business Advisor Ms. Andrea EpsteinControllerMore ExecutivesKey CompetitorsAcasti PharmaNASDAQ:ACSTUnity BiotechnologyNASDAQ:UBXEnlivex TherapeuticsNASDAQ:ENLVLipocineNASDAQ:LPCNBiora TherapeuticsNASDAQ:BIORView All CompetitorsInsidersOren GiladBought 2,000 shares on 3/13/2024Total: $14,580.00 ($7.29/share)Bernd R SeizingerBought 6,860 shares on 3/13/2024Total: $50,009.40 ($7.29/share)John P HamillBought 1,010 shares on 3/13/2024Total: $7,362.90 ($7.29/share)Bernd R SeizingerBought 4,068 shares on 6/6/2023Total: $14,766.84 ($3.63/share)View All Insider Transactions APRE Stock Analysis - Frequently Asked Questions Should I buy or sell Aprea Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APRE shares. View APRE analyst ratings or view top-rated stocks. What is Aprea Therapeutics' stock price target for 2024? 2 brokers have issued 12 month target prices for Aprea Therapeutics' shares. Their APRE share price targets range from $11.00 to $20.00. On average, they predict the company's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price. View analysts price targets for APRE or view top-rated stocks among Wall Street analysts. How have APRE shares performed in 2024? Aprea Therapeutics' stock was trading at $4.70 at the beginning of the year. Since then, APRE stock has increased by 25.3% and is now trading at $5.89. View the best growth stocks for 2024 here. When is Aprea Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our APRE earnings forecast. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics, Inc. (NASDAQ:APRE) issued its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.36. The company earned $0.01 million during the quarter, compared to the consensus estimate of $0.33 million. When did Aprea Therapeutics' stock split? Shares of Aprea Therapeutics reverse split on Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN). When did Aprea Therapeutics IPO? Aprea Therapeutics (APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO. Who are Aprea Therapeutics' major shareholders? Aprea Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Eyal C Attar, Gregory Alan Korbel, John P Hamill, Lars B Abrahmsen and Oren Gilad. View institutional ownership trends. How do I buy shares of Aprea Therapeutics? Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APRE) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
